# QBitaLabs Target Investor Research

**CONFIDENTIAL**

*Last Updated: January 2026*

---

## Investment Thesis Alignment

QBitaLabs sits at the convergence of three major investment themes:

1. **Quantum Computing** - $1.25B+ raised in Q1 2025 alone
2. **AI-Enabled Healthcare** - 62% of digital health VC dollars in 2025
3. **Precision Medicine** - $6.4B in H1 2025 digital health funding

---

## Tier 1: Primary Targets (Best Fit)

### Specialized Quantum VCs

#### 1. Quantonation
- **HQ**: Paris, France
- **Fund Size**: Quantonation II (active)
- **Stage**: Pre-seed to Series A, select Series B
- **Thesis**: Deep tech quantum computing applications
- **Notable Investments**: Pasqal, Quandela, Alice & Bob, Multiverse Computing
- **Fit Score**: ⭐⭐⭐⭐⭐

**Why Target**:
- Only dedicated quantum VC in Europe
- Strong track record in quantum startups
- Active in healthcare/life science quantum applications
- Would provide strong signal to market

**Key Contact**: Christophe Jurczak (Founding Partner)

**Approach Strategy**:
- Reference their investment in Multiverse Computing (quantum optimization)
- Emphasize our healthcare domain expertise as differentiator
- Request intro through academic quantum networks

---

#### 2. QAI Ventures
- **HQ**: Singapore (APAC HQ), Global presence
- **Fund Size**: Undisclosed, backed by Enterprise Singapore
- **Stage**: Seed to Series B
- **Thesis**: QuantumAI convergence
- **Notable Focus**: Building global QuantumAI ecosystem
- **Fit Score**: ⭐⭐⭐⭐⭐

**Why Target**:
- Perfect thesis alignment (Quantum + AI)
- APAC expansion potential
- Government backing provides credibility
- Ecosystem access to quantum computing partners

**Key Contact**: Management team via Enterprise Singapore network

**Approach Strategy**:
- Highlight APAC market opportunity (Japan pharma, Singapore biotech)
- Emphasize platform approach vs. point solutions
- Reference their QuantumAI thesis explicitly

---

#### 3. Columbus Venture Partners
- **HQ**: Madrid, Spain
- **Fund Size**: €100M+
- **Stage**: Series A focus
- **Thesis**: Quantum Computing + Health Tech
- **Notable Investments**: Multiverse Computing, Curve Therapeutics
- **Fit Score**: ⭐⭐⭐⭐⭐

**Why Target**:
- Explicit focus on Quantum + Healthcare intersection
- Curve Therapeutics investment shows drug discovery interest
- European presence complements US operations

**Key Contact**: Manuel Lopo (Managing Partner)

**Approach Strategy**:
- Reference Curve Therapeutics synergies
- Position as platform enabling multiple portfolio companies
- Emphasize regulatory pathway clarity

---

### Healthcare-Focused Deep Tech VCs

#### 4. Arch Venture Partners
- **HQ**: Chicago, IL
- **AUM**: $6B+
- **Stage**: Seed to Growth
- **Thesis**: Disruptive healthcare technologies
- **Notable Investments**: Illumina, Juno Therapeutics, Grail, Recursion
- **Fit Score**: ⭐⭐⭐⭐⭐

**Why Target**:
- Top-tier healthcare VC with deep pharma relationships
- Recursion investment shows AI drug discovery interest
- Can provide strategic pharma introductions
- Strong life science operator network

**Key Contact**: Robert Nelsen (Co-founder), Kristina Burow (Partner)

**Approach Strategy**:
- Emphasize differentiation from Recursion (quantum vs. classical)
- Focus on pharma pain points and ROI
- Leverage their pharma network for pilot customers

---

#### 5. Third Rock Ventures
- **HQ**: Boston, MA
- **AUM**: $5B+
- **Stage**: Seed to Series B (company building focus)
- **Thesis**: Build transformative healthcare companies
- **Notable Investments**: Agios, Bluebird Bio, Karuna
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Company-building approach (hands-on support)
- Deep pharma industry relationships
- Boston biotech ecosystem access
- Strong scientific advisory network

**Key Contact**: Neil Exter (Partner), Alexis Borisy (Partner)

**Approach Strategy**:
- Offer board seat and active involvement
- Emphasize scientific rigor and validation
- Request scientific advisor introductions

---

#### 6. Polaris Partners
- **HQ**: Boston, MA / Palo Alto, CA
- **AUM**: $4B+
- **Stage**: Early to Growth
- **Thesis**: Healthcare and technology innovation
- **Notable Investments**: Moderna, 10x Genomics, Twist Bioscience
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Moderna investment shows platform thinking
- 10x Genomics shows multi-omics interest
- Bi-coastal presence helpful

**Key Contact**: Amy Schulman (Managing Partner), Amir Nashat (Partner)

**Approach Strategy**:
- Position as platform enabling next Moderna-level breakthrough
- Emphasize precision medicine applications
- Highlight multi-omics integration capabilities

---

### General Tech VCs with Quantum Interest

#### 7. DCVC (Data Collective)
- **HQ**: San Francisco, CA
- **AUM**: $3B+
- **Stage**: Seed to Growth
- **Thesis**: Deep tech, AI, computational approaches
- **Quantum Portfolio**: Rigetti Computing, Q-CTRL
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Existing quantum portfolio (Rigetti, Q-CTRL)
- Computational biology interest
- Deep tech focus aligns with our approach
- Can provide technical due diligence support

**Key Contact**: Matt Ocko (Co-Founder), Zachary Bogue (Co-Founder)

**Approach Strategy**:
- Reference Q-CTRL investment (error correction synergies)
- Emphasize computational biology applications
- Position as application layer on quantum infrastructure

---

#### 8. Andreessen Horowitz (a16z Bio)
- **HQ**: Menlo Park, CA
- **AUM**: $35B+ (a16z overall), dedicated Bio fund
- **Stage**: Seed to Growth
- **Thesis**: Software-defined biology, AI drug discovery
- **Quantum Interest**: Rigetti early investor
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Massive platform and brand value
- a16z Bio dedicated to life sciences
- Strong AI/ML expertise in portfolio support
- Can help with enterprise sales

**Key Contact**: Vijay Pande (Partner, Bio), Jorge Conde (Partner, Bio)

**Approach Strategy**:
- Vijay Pande has computational chemistry background (perfect fit)
- Emphasize "software eating biology" narrative
- Reference their thesis on computational approaches

---

#### 9. GV (Google Ventures)
- **HQ**: Mountain View, CA
- **AUM**: $8B+
- **Stage**: Seed to Growth
- **Thesis**: Deep tech, healthcare, AI
- **Notable Investments**: Tempus, Verily, Oscar
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Google's quantum computing leadership (synergies)
- Strong AI/ML support services
- Tempus investment shows healthcare data interest
- GCP integration opportunities

**Key Contact**: Krishna Yeshwant (Managing Partner, Life Sciences)

**Approach Strategy**:
- Emphasize Google Cloud integration potential
- Reference their quantum computing program
- Position as application layer for Google's quantum hardware

---

#### 10. Lux Capital
- **HQ**: New York, NY
- **AUM**: $5B+
- **Stage**: Seed to Growth
- **Thesis**: Sci-fi into science fact
- **Notable Investments**: Recursion, Eikon Therapeutics, Atomic AI
- **Fit Score**: ⭐⭐⭐⭐

**Why Target**:
- Deep tech DNA
- Recursion investment (complementary, not competitive)
- Atomic AI shows computational biology interest
- Strong brand in frontier tech

**Key Contact**: Josh Wolfe (Co-founder), Peter Hébert (Co-founder)

**Approach Strategy**:
- Emphasize "sci-fi into reality" narrative
- Position quantum-bio convergence as the next frontier
- Reference Atomic AI synergies

---

## Tier 2: Secondary Targets (Good Fit)

### Healthcare AI Specialists

#### 11. General Catalyst (Health Assurance)
- **Focus**: Healthcare transformation
- **Notable**: Lila Sciences ($550M AI life sciences)
- **Fit**: Healthcare AI platform play
- **Contact**: Hemant Taneja

#### 12. Flagship Pioneering
- **Focus**: Life sciences platform companies
- **Notable**: Moderna (built from scratch)
- **Fit**: Platform company building
- **Contact**: Noubar Afeyan

#### 13. Khosla Ventures
- **Focus**: Bold technology bets
- **Notable**: OpenAI, Impossible Foods
- **Fit**: Frontier tech with impact
- **Contact**: Vinod Khosla, Samir Kaul (Health)

#### 14. 8VC
- **Focus**: Healthcare, logistics, deep tech
- **Notable**: Oscar, Zipline
- **Fit**: Healthcare technology
- **Contact**: Joe Lonsdale

### Digital Health Specialists

#### 15. General Atlantic
- **Focus**: Growth equity, healthcare IT
- **Notable**: Tempus
- **Fit**: Later stage or larger rounds

#### 16. Venrock
- **Focus**: Healthcare and technology
- **Notable**: Illumina, Athenahealth
- **Fit**: Healthcare platforms

#### 17. Felicis Ventures
- **Focus**: Enterprise and healthcare
- **Quantum Interest**: Protein Qure ($4M Seed)
- **Fit**: Quantum + healthcare intersection

---

## Tier 3: Corporate Strategic Investors

### Pharmaceutical CVCs

| Company | CVC Arm | Focus | Strategic Value |
|---------|---------|-------|-----------------|
| Pfizer | Pfizer Ventures | Drug discovery innovation | Pilot customer + investor |
| Roche | Roche Venture Fund | Diagnostics, precision med | Digital pathology synergy |
| Novartis | Novartis Venture Fund | AI drug discovery | Large molecule focus |
| J&J | Johnson & Johnson Innovation | MedTech, pharma | Broad portfolio access |
| Merck | Merck GHI | Healthcare innovation | Global reach |
| AstraZeneca | AZ Ventures | Oncology, respiratory | Recent AI deals ($5B+) |

**Approach Strategy for Pharma CVCs**:
- Start with commercial pilot, not investment discussion
- Build relationship through R&D collaboration
- Investment follows successful pilot (12-18 months)

### Technology CVCs

| Company | CVC Arm | Strategic Value |
|---------|---------|-----------------|
| Google | GV | Quantum hardware access, cloud |
| Microsoft | M12 | Azure Quantum, enterprise |
| Amazon | Amazon Ventures | AWS Braket, healthcare |
| IBM | IBM Ventures | Quantum systems access |
| NVIDIA | NVentures | GPU + quantum computing |

**Approach Strategy for Tech CVCs**:
- Position as application layer on their infrastructure
- Offer co-marketing and case studies
- Emphasize enterprise customer access

### Healthcare System CVCs

| System | CVC/Innovation | Strategic Value |
|--------|----------------|-----------------|
| Kaiser | Kaiser Permanente Ventures | 12M patient population |
| Mayo Clinic | Mayo Clinic Ventures | Clinical validation |
| Cleveland Clinic | CC Innovations | Cardiology expertise |
| Mass General Brigham | Mass General Brigham Ventures | Boston ecosystem |

---

## Investor Outreach Prioritization

### Phase 1: Pre-Series A (Current)

| Priority | Investor | Reason |
|----------|----------|--------|
| 1 | Quantonation | Quantum specialist, strong signal |
| 2 | Arch Venture Partners | Healthcare + pharma network |
| 3 | DCVC | Quantum portfolio, computational focus |
| 4 | a16z Bio | Platform + brand value |
| 5 | Columbus Venture Partners | Quantum + health intersection |

### Phase 2: Series A Syndicate Building

**Target Lead**: Arch Venture Partners or DCVC ($15M)

**Target Participants**:
- Quantonation ($3M) - Quantum expertise
- GV ($3M) - Google relationship
- Lux Capital ($2M) - Deep tech credibility
- Pharma CVC ($2M) - Strategic validation

### Phase 3: Post-Series A Expansion

- Strategic investors for Series B
- International VCs for global expansion
- Crossover investors for pre-IPO

---

## Warm Introduction Paths

### Academic Networks

| Connection | Potential Intros |
|------------|------------------|
| MIT Quantum | Quantonation, DCVC, The Engine |
| Stanford Chemistry | a16z Bio, Khosla, GV |
| Caltech Quantum | Lux Capital, Felicis |

### Industry Networks

| Connection | Potential Intros |
|------------|------------------|
| Ex-Pharma Executives | Pharma CVCs, Arch, Third Rock |
| Quantum Computing Conference | Quantonation, QAI Ventures |
| JP Morgan Healthcare | All healthcare VCs |

### Portfolio Company Referrals

| Company | Shared Investor | Warm Path |
|---------|-----------------|-----------|
| Recursion | Lux, Arch | Non-competitive, complementary |
| Rigetti | DCVC, a16z | Application layer pitch |
| Multiverse Computing | Quantonation, Columbus | Healthcare vertical |

---

## Due Diligence Preparation by Investor Type

### For Quantum Specialists

- Technical architecture deep dive
- Quantum advantage benchmarks
- Hardware partnership roadmap
- Patent portfolio analysis

### For Healthcare VCs

- Clinical validation pathway
- FDA regulatory strategy
- Pharma partnership pipeline
- Health economics / ROI models

### For General Tech VCs

- Total addressable market analysis
- Competitive moat analysis
- Go-to-market strategy
- Team and hiring plan

---

## Appendix: Investor Contact Database

*[Maintained separately in CRM]*

### Key Fields to Track

- Investor name and firm
- Focus areas and thesis
- Check size and stage
- Portfolio companies (synergies/conflicts)
- Key partners and contact info
- Introduction path
- Last contact date
- Status and next steps

---

**Sources**:
- [Rho: VCs in Quantum Computing](https://www.rho.co/blog/vcs-in-quantum-computing)
- [SeedTable: Quantum Investors 2025](https://www.seedtable.com/investors-quantum-computing)
- [The Quantum Insider: Top Quantum Investors](https://thequantuminsider.com/2022/06/08/quantum-investors/)
- [OpenVC: HealthTech Investors](https://www.openvc.app/investor-lists/healthtech-investors)
- [Crunchbase: AI Healthcare Funding](https://news.crunchbase.com/health-wellness-biotech/ai-healthcare-funding-rises-2025/)
